Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1951 1
1954 1
1957 2
1958 2
1959 1
1961 1
1962 1
1963 2
1965 1
1966 1
1967 1
1968 1
1969 1
1970 1
1972 1
1973 3
1974 1
1975 1
1978 1
1980 1
1984 1
1986 2
1987 6
1988 5
1989 3
1991 2
1992 2
1994 5
1995 2
1996 3
1997 5
1998 6
1999 5
2000 4
2001 4
2002 8
2003 4
2004 6
2005 4
2006 8
2007 11
2008 11
2009 10
2010 9
2011 10
2012 9
2013 12
2014 16
2015 14
2016 7
2017 13
2018 12
2019 10
2020 9
2021 23
2022 22
2023 28
2024 8

Text availability

Article attribute

Article type

Publication date

Search Results

316 results

Results by year

Filters applied: . Clear all
Page 1
Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma.
Choueiri TK, Tomczak P, Park SH, Venugopal B, Ferguson T, Chang YH, Hajek J, Symeonides SN, Lee JL, Sarwar N, Thiery-Vuillemin A, Gross-Goupil M, Mahave M, Haas NB, Sawrycki P, Gurney H, Chevreau C, Melichar B, Kopyltsov E, Alva A, Burke JM, Doshi G, Topart D, Oudard S, Hammers H, Kitamura H, Bedke J, Perini RF, Zhang P, Imai K, Willemann-Rogerio J, Quinn DI, Powles T; KEYNOTE-564 Investigators. Choueiri TK, et al. N Engl J Med. 2021 Aug 19;385(8):683-694. doi: 10.1056/NEJMoa2106391. N Engl J Med. 2021. PMID: 34407342 Free article. Clinical Trial.
Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Powles T, Tomczak P, Park SH, Venugopal B, Ferguson T, Symeonides SN, Hajek J, Gurney H, Chang YH, Lee JL, Sarwar N, Thiery-Vuillemin A, Gross-Goupil M, Mahave M, Haas NB, Sawrycki P, Burgents JE, Xu L, Imai K, Quinn DI, Choueiri TK; KEYNOTE-564 Investigators. Powles T, et al. Lancet Oncol. 2022 Sep;23(9):1133-1144. doi: 10.1016/S1470-2045(22)00487-9. Lancet Oncol. 2022. PMID: 36055304 Free article. Clinical Trial.
Reply by Authors.
Chiu PK, Leow JJ, Chiang CH, Mok A, Zhang K, Hsieh PF, Zhu Y, Lam W, Tsang WC, Fan YH, Lin TP, Chan TY, Leung CH, Teoh JY, Chu PS, Zhu G, Ye DW, Wu HC, Tan TW, Tsu JH, Ng CF, Chiong E, Huang CY. Chiu PK, et al. Among authors: lin tp. J Urol. 2023 Jul;210(1):98. doi: 10.1097/JU.0000000000003450.02. Epub 2023 May 4. J Urol. 2023. PMID: 37139611 No abstract available.
Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma.
Choueiri TK, Tomczak P, Park SH, Venugopal B, Ferguson T, Symeonides SN, Hajek J, Chang YH, Lee JL, Sarwar N, Haas NB, Gurney H, Sawrycki P, Mahave M, Gross-Goupil M, Zhang T, Burke JM, Doshi G, Melichar B, Kopyltsov E, Alva A, Oudard S, Topart D, Hammers H, Kitamura H, McDermott DF, Silva A, Winquist E, Cornell J, Elfiky A, Burgents JE, Perini RF, Powles T; KEYNOTE-564 Investigators. Choueiri TK, et al. N Engl J Med. 2024 Apr 18;390(15):1359-1371. doi: 10.1056/NEJMoa2312695. N Engl J Med. 2024. PMID: 38631003 Clinical Trial.
Symmetrical Nasal Ectopia Lentis.
Wang X, Lin TPH. Wang X, et al. Among authors: lin tph. Asia Pac J Ophthalmol (Phila). 2022 Jan 20;11(1):88. doi: 10.1097/APO.0000000000000475. Asia Pac J Ophthalmol (Phila). 2022. PMID: 35066526 Free article. No abstract available.
TGF-β signaling networks in the tumor microenvironment.
Chan MK, Chung JY, Tang PC, Chan AS, Ho JY, Lin TP, Chen J, Leung KT, To KF, Lan HY, Tang PM. Chan MK, et al. Among authors: lin tp. Cancer Lett. 2022 Dec 1;550:215925. doi: 10.1016/j.canlet.2022.215925. Epub 2022 Sep 29. Cancer Lett. 2022. PMID: 36183857 Review.
Tuberculous empyema.
Bai KJ, Wu IH, Yu MC, Chiang IH, Chiang CY, Lin TP, Lee YC, Luh KT. Bai KJ, et al. Among authors: lin tp. Respirology. 1998 Dec;3(4):261-6. doi: 10.1111/j.1440-1843.1998.tb00132.x. Respirology. 1998. PMID: 10201053
Simulate SubQ: The Methods and the Media.
Li D, Chow PY, Lin TP, Cheow C, Li Z, Wacker MG. Li D, et al. Among authors: lin tp. J Pharm Sci. 2023 Jun;112(6):1492-1508. doi: 10.1016/j.xphs.2021.10.031. Epub 2021 Oct 30. J Pharm Sci. 2023. PMID: 34728176 Review.
Optic neuropathy in high myopia: Glaucoma or high myopia or both?
Zhang X, Jiang J, Kong K, Li F, Chen S, Wang P, Song Y, Lin F, Lin TPH, Zangwill LM, Ohno-Matsui K, Jonas JB, Weinreb RN, Lam DSC; Glaucoma Suspects with High Myopia Study Group. Zhang X, et al. Among authors: lin tph. Prog Retin Eye Res. 2024 Mar;99:101246. doi: 10.1016/j.preteyeres.2024.101246. Epub 2024 Jan 21. Prog Retin Eye Res. 2024. PMID: 38262557 Review.
WLS-Wnt signaling promotes neuroendocrine prostate cancer.
Bland T, Wang J, Yin L, Pu T, Li J, Gao J, Lin TP, Gao AC, Wu BJ. Bland T, et al. Among authors: lin tp. iScience. 2021 Jan 1;24(1):101970. doi: 10.1016/j.isci.2020.101970. eCollection 2021 Jan 22. iScience. 2021. PMID: 33437943 Free PMC article.
316 results